Price alert —
Sign in to get a one-time email the moment PFE crosses your price. Free accounts included.
Sign in / create a free accountPfizer, Inc.: Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
PFE last traded at $25.05, down 0.4% on the day; that's in the lower part of its 52-week range ($23.62–$28.75). Right now it's trading close to its recent average, with no strong stretch in either direction.
The next scheduled earnings report (2026-08-04) is the biggest known catalyst on the calendar, and day to day, watch whether it holds above or slips below its recent average.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
KC1 upper, +0.73 ATR from EMA21 — no notable pattern
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
- · KC1 upper stretch — light pop
- · RSI rolling over (54)
- · Aligned with weak downtrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Our cash-flow model pegs fair value near $29.97 (fair range $24–$45); today's price leaves a +20% cushion below that estimate. The model's verdict is “Undervalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Positive retained earnings
- ✓ Gross margin 75% (pricing power)
- ⚠ Debt exceeds cash
- ⚠ Quick ratio 0.67 (fragile)
- ⚠ Receivables growing faster than revenue
Price implies ~3% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
PFE is a $142.8 billion company, priced at 19× last year's earnings, and it moves more calmly than the market (beta 0.3).
Options idea
See more →About
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vy…